37 results about "Glycopyrronium bromide" patented technology

The invention discloses a budeagfor inhalation dry powder inhalation which comprises active ingredients, a carrier and a dispersing aid, and the active ingredients are budesonide, glycopyrronium bromide and formoterol fumarate dihydrate which are subjected to particle size grading. According to the invention, different drugs can be delivered to respective target sites of the lung through a particle size grading process of micronized active ingredients. The budigegfu inhalation dry powder inhalation is good in delivery dose uniformity and stable in delivery efficiency, and animal test results show that the product prepared by adopting the active component size grading method has obvious advantages in the aspects of safety and effectiveness.

Aqueous formulations of indacaterol and glycopyrronium are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

The utility model relates to the technical field of pipettes, in particular to a pipette for glycopyrronium bromide neostigmine injection, which comprises a pipette main body, a sleeve is arranged at the bottom of the pipette main body, a movable clamping groove is arranged on the outer side of the sleeve, the inner wall of the top of the movable clamping groove is rotatably connected with a rotating screw rod, and a placing circular groove is arranged on the inner side of the movable clamping groove close to the top end. When the pipette main body sucks injection, the depth of the needle inserted into the injection is adjusted and fixed through the cooperation of the rotating screw rod, the limiting plate and other structures according to the height of the injection in a container, and the pipette main body is in a vertical state through the cooperation of the angle scale and other structures; therefore, it can be easily ensured that the insertion depth of the needle head is consistent every time, the pipette body is in a vertical state when the pipette body sucks injection, the accuracy of the pipette body in each time of pipetting is greatly improved, and the reliability of experimental results and the effectiveness of treatment are guaranteed.

Provided in the present invention are a suspended triple inhalation aerosol composition and a preparation method therefor. The aerosol composition comprises fluticasone furoate, vilanterol trifenatate, glycopyrrolate, a diluent, a surfactant and a propellant; has higher drug-delivery efficiency and drug-delivery dose, and higher lung deposition; and has the effects of better ameliorating Mch-induced elevated pulmonary resistance and decreased pulmonary compliance, thereby facilitating improvement to medication safety and patient compliance.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

The invention discloses a method for detecting the content of budesonide, formoterol and glycopyrronium bromide in budeagford inhalation aerosol, and relates to the technical field of drug detection and analysis, and the method comprises the following steps: preparing a test solution and a reference solution; detecting the contents of budesonide, formoterol and glycopyrronium bromide in the test solution and the reference solution by adopting a high performance liquid chromatography ultraviolet detector method; the detection conditions are as follows: octadecyl bonded silica gel is used as a filler, absolute ethyl alcohol-sodium dihydrogen phosphate solution is used as a mobile phase A, absolute ethyl alcohol-sodium dihydrogen phosphate solution-acetonitrile is used as a mobile phase B, and gradient elution is performed; the detection wavelength of the formoterol and the glycopyrronium bromide is 214 nm, and the detection wavelength of the budesonide is 254 nm. The detection method can simultaneously detect the contents of budesonide, formoterol fumarate and glycopyrronium bromide, has good specificity and high accuracy, and can effectively reduce the subsequent detection cost.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a detection method and application of related substances of glycopyrronium bromide neostigmine injection. The related substances of the glycopyrronium bromide neostigmine injection are detected by adopting a high performance liquid chromatography, taking an aqueous solution of potassium dihydrogen phosphate and sodium heptanesulfonate as a mobile phase A and taking acetonitrile as a mobile phase B for gradient elution. In addition, the content of related substances can be calculated according to a main component reference substance external standard method with correction factors. The detection method provided by the invention has relatively high specificity and sensitivity, and excellent precision, accuracy and durability.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

The utility model relates to the technical field of dilution preparation of injection, in particular to a dilution preparation device for glycopyrronium bromide neostigmine injection, which comprises a tank body, a tank cover is arranged at the top of the tank body, a sealing plate is arranged at the joint of the tank body and the tank cover, a first motor is arranged at the top of the tank cover, the output end of the first motor is fixedly connected with a rotating rod, and the rotating rod is fixedly connected with the tank cover. A plurality of lantern rings are arranged on the outer side of the rotating rod, stirring plates are symmetrically arranged on the outer sides of the lantern rings, and feeding nozzles are arranged between the lantern rings. The first motor drives the rotating rod to rotate, the rotating rod rotates to drive the lantern ring and the stirring plate to rotate together, and the stirring plate can be more conveniently detached through the lantern ring, so that the stirring plate is replaced and maintained; the first motor is used for driving the stirring plate to rotate at a low speed, so that injection in the tank body and diluent in the feeding box are stirred and mixed, and meanwhile, other diluent with a small dosage is added through the feeding spray head in the rotating rod.

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

A method and formulation is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity.

The present invention provides a glycopyrronium bromide intermediate and its preparation method and application, and relates to the technical field of chemical synthesis. The preparation method of glycopyrronium bromide intermediate comprises the following steps: using α-cyclopentylmandelic acid methyl ester as raw material, and 1,4-dibromo-2-butanol undergoes ester exchange reaction under the action of a first base catalyst to obtain a glycopyrronium bromide intermediate, i.e., compound 2. The preparation method of glycopyrronium bromide comprises the following steps: compound 2 undergoes quaternization reaction with dimethylamine under the action of a second base catalyst to obtain glycopyrronium bromide. The raw materials of the present invention are cheap and easy to obtain, and the use of toxic gas methyl bromide commonly used in the prior art is avoided, the environmental pollution is small, the green environmental protection, the reaction conditions are mild, the reaction process is easy to control, the use of metallic sodium is avoided, the operation is safe, the safety factor is high, and the reaction steps are greatly reduced, the production cost is saved, the product yield obtained is high, the purity is high, and a process route for industrial production of higher quality products is provided.

The present invention relates to a process for preparing a powder formulation for inhalation for use in a dry powder inhaler, the powder formulation comprising: (A) a carrier comprising: (a) a physiologically acceptable coarse particle fraction of the carrier having a particle size of at least 60 microns; and optionally (b) a fine particle fraction comprising a physiologically acceptable excipient wherein at least 90% of all of the fine particles have a volume diameter of less than 15 microns, (B) micronized particles of glycopyrronium bromide, an inhalation corticosteroid (ICS) and optionally a long-acting beta2-agonist (LABA) as active ingredients, wherein the method comprises: (i) preparing, by co-grinding, microparticles consisting of glycopyrronium bromide and a first portion of ICS in a weight ratio of 80: 20 to 70: 30, wherein the volume diameter of the microparticles is not greater than 15 microns; (ii) mixing a carrier, the remainder of the ICS and an optional long-acting beta2-agonist to obtain a first mixture; and (iii) adding the co-milled microparticles obtained in step (i) to the first mixture obtained in step (ii) to obtain a second final mixture.

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg / mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

A pharmaceutical composition is described. The composition comprises a drug component consisting of at least one indacaterol compound selected from indacaterol and indacaterol maleate, and at least one pharmaceutically acceptable salt of glycopyrrolate; and a propellant component at least 90 weight % of which is 1,1-difluoroethane (HFA-152a).

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

The invention provides a surface anesthetic with oral mucosa adhesiveness and salivation resistance and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises lidocaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

An inhalation powder containing 24.1 μg of glycopyrronium bromide and 12.7 μg of formoterol fumarate dihydrate per unit dose is disclosed. The powder shows a clear bronchodilatory effect in patients with COPD after twice daily administration. After repeated administration, the lung function of the patients is significantly improved.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated canister, which formulation is particularly useful for use in pressurized metered dose inhalers for the treatment of respiratory diseases.

The invention provides application of glycopyrronium bromide in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of biological medicines. The research finds that the novel drug glycopyrronium bromide shows a clear and excellent technical effect in the aspect of treating nervous system diseases, on one hand, the glycopyrronium bromide can inhibit the inflammatory response of glial cells by reducing infiltration of central mononuclear macrophages (MDM); on the other hand, differentiation and maturation of oligodendroglia precursor cells (OPCs) into oligodendroglia cells can be effectively promoted, and the effect of promoting myelin sheath regeneration is achieved. Multiple sclerosis is effectively improved through the dual effects of inhibiting glial cell inflammation and promoting myelin regeneration, and the medicine is a candidate medicine with great potential for treating progressive multiple sclerosis (MS).

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

Individually packaged topical formulations comprising about 0.25 to about 6% w / w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.

Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

The utility model belongs to the production technology field of glycopyrronium bromide, specifically relates to a glycopyrronium bromide production waste treatment device. Including water washing bucket and alkali washing bucket, be linked to the connecting pipe between water washing bucket and alkali washing bucket, be equipped with the air inlet pipe on water washing bucket, be equipped with the exhaust pipe on alkali washing bucket, be equipped with water washing subassembly in water washing bucket, be equipped with high -efficient stirring subassembly in alkali washing bucket. The utility model discloses through the structure improvement, can carry out the adjustment of the stirring blade angle according to the concentration of the acid gas produced in the production process, and the small -angle stirring blade satisfies the stirring of small -density gas, and the big -angle stirring blade satisfies the stirring of high -density gas, can make motor release different power, effectively reduce the cost of use.

The invention provides a surface anesthetic with oral mucosa adhesiveness, salivation resistance and taste improvement effects and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises tetracaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

Disclosed is a pharmaceutical composition for inhalation, comprising long-acting β2 agonist and long-acting muscarinic antagonist. The long-acting β2 agonist comprises olodaterol; or long-acting β2 agonist comprises arformoterol, and the pH of the composition is 3.5-5.5; or long-acting β2 agonist comprises indacaterol, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises revefenacin, and the pH of the composition is 3.5-5.5; or the long-acting muscarinic antagonist comprises glycopyrronium bromide, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises tiotropium bromide, and the pH of the composition is 2.0-4.0. Disclosed is a use of the pharmaceutical composition for inhalation for the preventing or treating of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and the like.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.